|
R&D Pipeline News Vol. 2, Issue 18: Interferons |
|
|
|
15 May 2006 |
Read the highlights of the most recent edition of our weekly R&D information product R&D Pipeline News. The Special Product or Technology Pipelines of R&D Pipeline News are available via subscription of R&D Pipeline News or as a single Project Pipeline List .
 |
| |
Featured Pipeline: Interferons
|
Vol. 2 Issue nº 18
May 15, 2006
|
 |
|
|
Featured Pipeline: Interferons
|
Interferon alpha
|
- Combined 2005 sales of rhu interferon alpha more than US$ 2.1 bln;
- Market conversion from 1 st generation interferon alpha to pegylated 2 nd generation nearly completed;
- First biosimilar interferon alpha filed with EMEA;
- Longer acting interferon alpha projects in clinical development;
- Evaluation of interferon alpha subtypes different from alpha2 ongoing;
- Search for modified interferon alpha molecules with improved pharmacodynamic profile
|
Interferon beta
|
- Combined 2005 sales of rhu interferon beta more than US$ 3.8 bln;
- Biosimilar interferon beta under development;
- Modified interferon beta with longer half-life or improved pharmacodynamic profile in early development;
|
Interferon gamma
|
- Limited commercial attractiveness;
- Clinical develolpment in idiopathic pulmonary fibrosis not yet completed;
- Search for molecules with improved pharmacodynamic profile
|
Other interferons
|
- Clinical proof of concept with 1 st generation molecules;
- Follow-on projects with longer acting constructs;
|
Interferon gene therapy
|
- Pilot clinical studies ongoing;
- Focus on cancer indications;
- Viral and non-viral delivery systems used
|
|
|
You can get this complete report just ordering now your Subscription!
|
R&D Pipeline News
Get your Subscription Now
|
R&D Pipeline News is a premier information source about research and development (R&D) projects in the pipeline of the biopharmaceutical industry and is directed to all stakeholders in R&D . R&D Pipeline News covers all relevant treatment modalities, including. drugs, medical devices, biomaterials, combination products, cell therapy and drug delivery products.
Read more about R&D Pipeline NewsOrder Now
 
|
|
|
|
|
|
|
|
|
